Nektar Therapeutics (NKTR) EBITDA Margin (2010 - 2026)

Nektar Therapeutics' EBITDA Margin history runs 17 years deep, the most recent figure standing at 359.58% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 12707.0% year-over-year to 359.58%; the TTM figure through Mar 2026 stood at 61.87% (up 7951.0% YoY), while the FY2025 annual figure was 62.44%, up 4444.0% from the prior year.
• EBITDA Margin was 359.58% for Q1 2026 at Nektar Therapeutics, down from 357.46% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 357.46% in Q4 2025 to a low of 744.62% in Q2 2022.
• Historically, EBITDA Margin has averaged 259.61% across 5 years, with a median of 238.25% in 2022.
• The sharpest annual moves came in 2023 and 2025: EBITDA Margin jumped 49148 bps in 2023, then slumped 31435 bps in 2025.
• A 5-year view of EBITDA Margin shows it stood at 238.25% in 2022, then jumped by 41 bps to 140.3% in 2023, then jumped by 135 bps to 49.18% in 2024, then jumped by 627 bps to 357.46% in 2025, then slumped by 201 bps to 359.58% in 2026.
• The last three EBITDA Margin figures came in at 359.58% (Q1 2026), 357.46% (Q4 2025), and 268.63% (Q3 2025), per Business Quant data.